The DOI matches its OpenAlex record; 37 of the 37 references it cites were found in a registry or an index.
Foxo1 mediates insulin action on apoC-III and triglyceride metabolism
Open accessAbstract
The apolipoprotein apoC-III plays an important role in plasma triglyceride metabolism. It is predominantly produced in liver, and its hepatic expression is inhibited by insulin. To elucidate the inhibitory mechanism of insulin in apoC-III expression, we delivered forkhead box O1 (Foxo1) cDNA to hepatocytes by adenovirus-mediated gene transfer. Foxo1 stimulated hepatic apoC-III expression and correlated with the ability of Foxo1 to bind to its consensus site in the apoC-III promoter. Deletion or mutation of the Foxo1 binding site abolished insulin response and Foxo1-mediated stimulation. Likewise, Foxo1 also mediated insulin action on intestinal apoC-III expression in enterocytes. Furthermore, elevated Foxo1 production in liver augmented hepatic apoC-III expression, resulting in increased plasma triglyceride levels and impaired fat tolerance in mice. Transgenic mice expressing a constitutively active Foxo1 allele exhibited hypertriglyceridemia. Moreover, we show that hepatic Foxo1 expression becomes deregulated as a result of insulin deficiency or insulin resistance, culminating in significantly elevated Foxo1 production, along with its skewed nuclear distribution, in livers of diabetic NOD or db/db mice. While loss of insulin response is associated with unrestrained apoC-III production and impaired triglyceride metabolism, these data suggest that Foxo1 provides a molecular link between insulin deficiency or resistance and aberrant apoC-III production in the pathogenesis of diabetic hypertriglyceridemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · doi:10.1016/s0092-8674(04)00452-0 · Cited by 1,356
Biggs, W. H., Meisenhelder, J., Hunter, T., Cavenee, W. K., & Arden, K. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7421 · Cited by 1,116
Phosphorylation of the Transcription Factor Forkhead Family Member FKHR by Protein Kinase B
Rena, G., Guo, S., Cichy, S. C., Unterman, T. G., & Cohen, P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17179 · Cited by 714
Nakae, J., Kitamura, T., Silver, D. L., & Accili, D. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200112876 · Cited by 652
Nakae, J., Kitamura, T., Silver, D. L., & Accili, D. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12876 · Cited by 652
Nakae, J., Biggs, W. H., Kitamura, T., Cavenee, W. K., Wright, C. V. E., Arden, K. C., & Accili, D. (2002) · Nature Genetics · doi:10.1038/ng890 · Cited by 616
Kitamura, T., Nakae, J., Kitamura, Y., Kido, Y., Biggs, W., Wright, C. V. E., White, M. F., Arden, K. C., & Accili, D. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16857 · Cited by 580
Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic Mice
Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., & Breslow, J. L. (1990) · Science · doi:10.1126/science.2167514 · Cited by 539
Nakae, J., Park, B.-C., & Accili, D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.15982 · Cited by 470
Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.
Wang, C. S., McConathy, W. J., Kloer, H. U., & Alaupovic, P. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111711 · Cited by 414
Cited by
Pawlak, M., Lefebvre, P., & Staels, B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.039 · Cited by 1,578
Valsesia, A., Wang, Q.-P., Gheldof, N., Carayol, J., Ruffieux, H., Clark, T., Shenton, V., Oyston, L. J., Lefebvre, G., Metairon, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08492-8 · Cited by 1,073
Redox regulation of FoxO transcription factors
Klotz, L.-O., Sánchez-Ramos, C., Prieto-Arroyo, I., Urbánek, P., Steinbrenner, H., & Monsalve, M. (2015) · Redox Biology · doi:10.1016/j.redox.2015.06.019 · Cited by 747
“In other studies with transgenic mice, both overexpression of constitutively active Foxo1a as well as knockdown of Foxo1a and Foxo3a likewise resulted in hypertriglyceridemia [232,235].”
BackgroundPathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708
FoxO proteins in insulin action and metabolism
Barthel, A., Schmoll, D., & Unterman, T. G. (2005) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2005.03.010 · Cited by 604
Pathophysiology of Diabetic Dyslipidemia
Hirano, T. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17023 · Cited by 552
The role of FoxO in the regulation of metabolism
Gross, D. N., van den Heuvel, A. P. J., & Birnbaum, M. J. (2008) · Oncogene · doi:10.1038/onc.2008.25 · Cited by 540
FoxO1 Regulates Multiple Metabolic Pathways in the Liver
Zhang, W., Patil, S., Chauhan, B., Guo, S., Powell, D. R., Le, J., Klotsas, A., Matika, R., Xiao, X., Franks, R., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600272200 · Cited by 516
Inflammation and cardiovascular disease: From mechanisms to therapeutics
Alfaddagh, A., Martin, S. S., Leucker, T. M., Michos, E. D., Blaha, M. J., Lowenstein, C. J., Jones, S. R., & Toth, P. P. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100130 · Cited by 473
Matsumoto, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27047 · Cited by 436
Qiao, L., & Shao, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607215200 · Cited by 381
FoxO integration of insulin signaling with glucose and lipid metabolism
Lee, S., & Dong, H. H. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0002 · Cited by 360
Self-citationApolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282
Bo, T., Gao, L., Yao, Z., Shao, S., Wang, X., Proud, C. G., & Zhao, J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.006 · Cited by 293
FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice
Kamagate, A., Qu, S., Perdomo, G., Su, D., Kim, D. H., Slusher, S., Meseck, M., & Dong, H. H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32914 · Cited by 282
Self-citationNagashima, T., Shigematsu, N., Maruki, R., Urano, Y., Tanaka, H., Shimaya, A., Shimokawa, T., & Shibasaki, M. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065714 · Cited by 275
Chahil, T. J., & Ginsberg, H. N. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.06.002 · Cited by 233
The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00474 · Cited by 196
“The transcription rate of APOC3 is decreased by insulin (28, 29), peroxisome proliferator-activated receptor-α (PPARα) (30), and farnesoid X receptor (FXR) (Figure 1) (32).”
BackgroundPostprandial hypertriglyceridemia as a coronary risk factor
Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.015 · Cited by 182
The FoxO transcription factors and metabolic regulation
Nakae, J., Oki, M., & Cao, Y. (2008) · FEBS Letters · doi:10.1016/j.febslet.2007.11.025 · Cited by 176
Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0126 · Cited by 170
Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201
The emerging role of FOXO transcription factors in pancreatic β cells
Glauser, D. A., & Schlegel, W. (2007) · Journal of Endocrinology · doi:10.1677/joe-06-0191 · Cited by 153
FoxO1 integrates insulin signaling to VLDL production.
Kamagate, A., & Dong, H. H. (2008) · Cell Cycle · doi:10.4161/cc.7.20.6882 · Cited by 127
Self-citationApolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
Yao, Z., & Wang, Y. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dc70 · Cited by 100
Apolipoprotein CIII links dyslipidemia with atherosclerosis
Kawakami, A., & Yoshida, M. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e607 · Cited by 98
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
“A constitutively active FoxO1 mutation induces hypertriglyceridemia in mouse models, highlighting the additional significance of the AKT-FoxO1 axis in maintaining lipid homeostasis under normal physiological conditions [12,31].”
Modification of lipoprotein metabolism and function driving atherogenesis in diabetes
Luciani, L., Pedrelli, M., & Parini, P. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117545 · Cited by 72
Myeloid FoxO1 depletion attenuates hepatic inflammation and prevents nonalcoholic steatohepatitis
Lee, S., Usman, T. O., Yamauchi, J., Chhetri, G., Wang, X., Coudriet, G. M., Zhu, C., Gao, J., McConnell, R., Krantz, K., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154333 · Cited by 64
Self-citationGinsberg (2011) · doi:10.1161/atvbaha.110.221846 · Cited by 64
Lê, K.-A., & Bortolotti, M. (2008) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328302f3ec · Cited by 60
Charidemou, E., Ashmore, T., Li, X., McNally, B. D., West, J. A., Liggi, S., Harvey, M., Orford, E., & Griffin, J. L. (2019) · JCI Insight · doi:10.1172/jci.insight.124819 · Cited by 52
“FoxO1 is itself negatively regulated by insulin, which causes its phosphorylation and nuclear exclusion (41, 42).”
BackgroundOkon, E. B., Chung, A. W. Y., Zhang, H., Laher, I., & van Breemen, C. (2007) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y07-026 · Cited by 50
“Insulin resistance could result in increased lipid levels in blood (Altomonte et al. 2004).”
BackgroundInsulin Regulation of Hepatic Lipid Homeostasis
Uehara, K., Santoleri, D., Whitlock, A. E. G., & Titchenell, P. M. (2023) · Comprehensive Physiology · doi:10.1002/cphy.c220015 · Cited by 49
“A constitutively active FOXO1 mutation induces hypertriglyceridemia in mouse models, highlighting the additional significance of the AKT-FOXO1 axis in maintaining lipid homeostasis under normal physiological conditions (16).”
Hepatic ABCA1 and VLDL triglyceride production
Liu, M., Chung, S., Shelness, G. S., & Parks, J. S. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.020 · Cited by 43
Pan, B.-Y., Chen, C.-S., Chen, F.-Y., & Shen, M.-Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312759 · Cited by 19
Metadata
- Authors
- Altomonte, J., Lin, C., Harbaran, S., Richter, A. M., Xu, J., Meseck, M. L., & Dong, H. H.
- Venue
- Journal of Clinical Investigation
- Publisher
- American Society for Clinical Investigation
- Published
- 2004-11-15
- Volume
- 114
- Issue
- 10
- Pages
- 1493-1503
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2000962819
- Cited by
- 309
- References
- 37
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.